查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994338

人工肺市場：2026-2032年全球市場預測（依產品類型、技術、材料類型、最終用戶、應用及分銷通路分類）

Artificial Lung Market by Product Type, Technology, Material Type, End User, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工肺市場價值將達到 83.3 億美元，到 2026 年將成長至 90.9 億美元，到 2032 年將達到 172.4 億美元，複合年成長率為 10.94%。

主要市場統計數據
基準年 2025 83.3億美元
預計年份：2026年 90.9億美元
預測年份 2032 172.4億美元
複合年成長率 (%) 10.94%

全面概述了人工肺的發展趨勢，將設備工程的進步與不斷變化的臨床實踐和部署需求聯繫起來。

在重症監護創新和先進生物材料工程的交會點，人工肺部領域正迅速發展成熟。其發展動力源自於臨床上對人工呼吸器治療方法的新需求，以及改善重症呼吸衰竭治療效果的渴望。新型人工肺結構旨在以更高的生物相容性和便攜性模擬肺部氣體交換，同時治療流程也在不斷調整，以便在治療早期階段整合外部支持。隨著關注點從急性住院治療轉向門診和家庭支持的潛力，研發人員和醫療服務提供者必須在重症監護級別的性能、以用戶為中心的設計以及長期安全性之間取得平衡。

材料技術的突破、支持系統的微型化以及護理服務模式的變革，正在重新定義人工肺的引入和整合之路。

臨床團隊致力於研發能夠實現穩定氣體交換並最大限度減少血栓形成和發炎反應的裝置，而變革性的進展正在重塑人工肺技術的研發和應用。膜材料的創新正以高性能陶瓷和人工中空纖維取代傳統聚合物，從而提高耐久性和血液相容性。同時，驅動主機的小型化和血流動力學管理演算法的改進，使得更靈活的部署模式成為可能，包括移動式體外循環裝置和用於長期支援的潛在植入式結構。

本研究評估了 2025 年進口關稅上調對供應鏈韌性、籌資策略和產品開發計畫的結構性和營運性影響。

2025年實施的新關稅制度和貿易措施為人工肺部生產和分銷的整個供應鏈帶來了巨大摩擦。關鍵進口零件（例如精密泵浦、特殊薄膜和生物相容性聚合物）關稅的提高，增加了依賴跨境採購的組裝製造商的收貨成本。因此，採購團隊和生產負責人正在重新審視供應商選擇、避險策略和合約條款，以維持獲利能力和供應的連續性。

將產品架構、膜技術、終端用戶工作流程、應用場景、分銷方式和材料選擇與商業化策略聯繫起來的實用細分見解。

了解產品、技術、終端用戶、應用、分銷管道和材料類型等方面的細分，對於掌握人工肺領域的整體情況價值創造至關重要。產品差異化延伸至體外膜氧合（ECMO）系統和臨床試驗中的植入式人工肺，其中ECMO系統進一步細分為插管、主機、氧合器和泵，這些部件共同決定了手術的複雜程度和設備面積。技術選擇範圍廣泛，從陶瓷膜和板式膜到中空纖維膜結構，而中空纖維膜中聚醚碸和聚丙烯配方的差異決定了其在滲透性、耐久性和血液相容性方面的權衡。

為了加速人工肺技術在全球市場的普及，區域策略挑戰包括協調監管差異、臨床基礎設施和製造地。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管預期、報銷制度和生產物流有顯著影響。在美洲，臨床研究網路和重症監護基礎設施為先進的體外循環療法提供了支持，但市場准入和業務拓展需要應對不同的支付方方案和醫院採購通訊協定。同時，歐洲、中東和非洲地區的監管體係錯綜複雜，各國既有各自的評估標準和採購規範，也努力實現協調統一，這影響實施進度和臨床證據要求。

主要企業的發展趨勢和競爭需求，包括優先考慮膜技術創新、製造嚴謹性、臨床證據產生和分銷管道最佳化，以實現永續的差異化。

人工肺領域的競爭格局由成熟的醫療設備製造商、專業組件供應商以及致力於將轉化研究成果轉化為商業原型產品的臨床創新者共同構成​​。主要企業正加大對膜技術、泵浦效率和整合感測器系統的投入，以在性能、易用性和生命週期成本方面脫穎而出。醫療設備原始設備製造商 (OEM) 與材料專家之間的策略合作日益普遍，雙方攜手開發膜結構和血液相容性塗層，從而降低血栓形成和發炎反應。

為領導者提供極具影響力的建議，以協調模組化設計、供應商多元化、臨床證據計劃和客製化商業模式，從而加速推廣應用並增強韌性。

產業領導者應推行一項綜合性議程，同時兼顧技術成熟度、供應鏈韌性和臨床部署路徑。優先採用模組化設備架構將加速替代供應商的認證，並實現產品迭代更新，而無需對平台進行徹底重新設計。對膜和塗層技術的投資應與嚴格的血液學測試和人體工學設計相結合，以減少不利事件並簡化臨床醫生的工作流程。在供應鏈方面，組件來源多元化和探索區域性製造地可以縮短關鍵組裝前置作業時間，同時降低關稅風險和物流中斷的影響。

我們透過透明、以證據為基礎的調查方法來支持策略決策，該方法整合了對臨床醫生的訪談、材料和設備的分析、供應鏈映射和情境測試。

本研究途徑結合了多方面的證據基礎、專家定性訪談和結構化分析，旨在建構人工肺現狀的全面圖像。與臨床醫生、生物醫學工程師、監管顧問和採購專家的討論是了解臨床工作流程、設備性能優先順序和實際部署障礙的關鍵資訊來源。二手研究從多個角度檢視了材料科學領域的技術趨勢和進展，並利用了同行評審文獻、監管指導文件、專利和製造商的技術規範。設備架構和供應鏈佈局的比較檢驗有助於評估可製造性和物流風險。

將材料科學、設備便攜性、法規遵循和供應鏈韌性方面的突破性進展整合起來，為臨床部署和商業化提供了一條切實可行的途徑。

總之，膜材料、設備小型化和系統整合方面的進步正在為人工肺技術帶來轉折點，影響臨床實踐、供應鏈設計和商業化策略。從僅限醫院使用到門診治療，甚至未來可能植入式應用的轉變，需要一種綜合方法，將技術創新與臨床工作流程、監管合規性和支付方的評估相結合。關稅趨勢和區域製造的考量進一步凸顯了在更靠近市場的地方建立可靠的採購和生產方案的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工肺市場：依產品類型分類

  • 體外膜氧合裝置
    • 套管
    • 主機
    • 氧合器
    • 泵浦
  • 植入式人工肺

第9章 人工肺市場：依技術分類

  • 陶瓷膜
  • 平面膜
  • 中空纖維膜
    • 聚醚碸
    • 聚丙烯

第10章：人工肺市場：依材料類型分類

  • 聚醚碸
  • 聚丙烯
  • 矽酮

第11章 人工肺市場：依最終用戶分類

  • 門診部
  • 居家照護
  • 醫院

第12章 人工肺市場：依應用領域分類

  • 重症監護
  • 緊急運輸
  • 呼吸支持

第13章：人工肺市場：依通路分類

  • 直銷
    • 向診所銷售
    • 對於醫院
  • 銷售代理網路
    • 醫療設備批發商
    • 藥品批發商
  • 線上平台

第14章 人工肺市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：人工肺市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 人工肺市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國人工肺市場

第18章 中國人工肺市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abiomed, Inc.
  • ALung Technologies, Inc.
  • B. Braun Melsungen AG
  • Braile Biomedica
  • Eurosets Srl
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Hemovent GmbH
  • Inspira Technologies OXY BHN
  • LivaNova PLC
  • MC3 Cardiopulmonary Support Inc.
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Spectrum Medical（UK）Limited
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-1A1A064C0598

The Artificial Lung Market was valued at USD 8.33 billion in 2025 and is projected to grow to USD 9.09 billion in 2026, with a CAGR of 10.94%, reaching USD 17.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.33 billion
Estimated Year [2026] USD 9.09 billion
Forecast Year [2032] USD 17.24 billion
CAGR (%) 10.94%

An integrative introduction to the evolving artificial lung landscape that connects advances in device engineering with shifting clinical practices and adoption imperatives

The artificial lung arena is rapidly maturing at the intersection of critical care innovation and advanced biomaterials engineering, driven by renewed clinical demand for alternatives to mechanical ventilation and improved outcomes in severe respiratory failure. Emerging device architectures aim to replicate pulmonary gas exchange with greater biocompatibility and portability, while procedural ecosystems adapt to integrate extracorporeal support earlier in the care pathway. As attention shifts from acute, in-hospital use toward ambulatory and home-support potential, developers and providers must reconcile intensive-care-grade performance with user-centric design and long-term safety profiles.

Concurrent advances in membrane technologies, pump miniaturization, and sensor-driven control systems are enabling more efficient extracorporeal platforms and nascent implantable solutions that could redefine chronic respiratory support. Regulatory frameworks and clinical evidence requirements are evolving to address these hybrid technologies, increasing the emphasis on real-world performance and human factors. Investors, supply chain partners, and clinical stakeholders are therefore tasked with navigating a highly technical landscape where translational research, manufacturability, and post-market surveillance are equally determinative of commercial success.

In this context, organizations should prioritize cross-disciplinary collaboration spanning materials science, critical care medicine, and regulatory strategy. By aligning technological roadmaps with clinical workflows and reimbursement realities, stakeholders can better bridge proof-of-concept milestones and sustainable adoption pathways for next-generation artificial lung systems.

How materials breakthroughs, miniaturization of support systems, and shifting care delivery models are jointly redefining pathways for artificial lung adoption and integration

Transformative shifts are reshaping the development and deployment of artificial lung technologies as clinical teams demand devices that deliver consistent gas exchange while minimizing thrombogenicity and inflammatory activation. Membrane material innovations are replacing legacy polymers with higher-performance ceramics and engineered hollow fibers, enhancing durability and hemocompatibility. At the same time, the miniaturization of drive consoles and the refinement of hemodynamic management algorithms are enabling more flexible deployment models, including mobile extracorporeal units and potential implantable constructs that are designed for longer-term support.

The clinical landscape is also changing in terms of care setting and stakeholder expectations. There is growing interest in extending extracorporeal support beyond intensive care units to pre-hospital emergency transport and ambulatory settings, which requires ruggedized devices, simplified interfaces, and telemonitoring capabilities. Concurrently, payer and procurement stakeholders are scrutinizing total cost of care and comparative effectiveness, pushing manufacturers to demonstrate not only technical superiority but also operational viability and clear pathways to reimbursement. These intersecting forces are producing a market environment where technological differentiation, clinical integration, and value demonstration are decisive for adoption trajectories.

Assessing the structural and operational consequences of escalated import duties in 2025 on supply chain resilience, sourcing strategies, and product development timelines

The imposition of new tariff regimes and trade measures in 2025 has introduced measurable friction across the supply chains that support artificial lung manufacturing and distribution. Increased duties on key imported components such as precision pumps, specialty membranes, and biocompatible polymers have elevated landed costs for assemblers that rely on cross-border sourcing. As a result, procurement teams and manufacturing planners are reassessing supplier concentration, hedging strategies, and contractual terms to preserve margin and continuity of supply.

Tariff-driven cost pressures have a cascading effect on product development timelines and commercial models. Engineering teams are under pressure to qualify alternative materials and suppliers more rapidly, while quality assurance functions must accelerate validation activities to maintain regulatory compliance. At the distribution level, channel partners are renegotiating pricing structures and service agreements to reflect higher input costs. Moreover, increased import duties are incentivizing nearshoring and regional manufacturing footprints, prompting capital allocation decisions to favor production sites closer to end markets to mitigate tariff exposure.

These dynamics also affect long-term strategic planning, as organizations balance the immediate need to absorb or pass through incremental costs with the broader objective of securing resilient supply chains. Stakeholders that proactively diversify supplier networks, invest in local manufacturing capability, and optimize product design for modularity are better positioned to manage tariff volatility while preserving access to critical components and technologies.

Actionable segmentation insights that connect product architecture, membrane technologies, end-user workflows, application scenarios, distribution approaches, and material selections to commercialization strategies

Understanding segmentation across product, technology, end user, application, distribution channel, and material type is essential for mapping value creation in the artificial lung domain. Product differentiation spans extracorporeal membrane oxygenation systems and investigational implantable artificial lungs, with extracorporeal systems further decomposed into cannula, consoles, oxygenators, and pumps that together determine procedural complexity and footprint. Technology choices range from ceramic and flat sheet membranes to hollow fiber configurations, and within hollow fibers, distinctions between polyethersulfone and polypropylene formulations inform trade-offs in permeability, durability, and hemocompatibility.

End users encompass ambulatory care centers, home care programs, and hospitals, each presenting distinct clinical workflows, staffing models, and procurement cycles that influence product requirements and support expectations. Applications vary across critical care, emergency transport, and respiratory support, and these use cases place different demands on device portability, setup time, and monitoring capabilities. Distribution channels include direct sales, distributor networks, and online platforms; direct sales models often target clinic and hospital accounts with integrated service offerings, while distributor relationships may leverage medical device and pharmaceutical distribution expertise to broaden market presence. Material selection, including polyethersulfone, polypropylene, and silicone, intersects with technology choice and device architecture to shape biocompatibility, sterilization pathways, and component longevity.

Taken together, these segmentation layers create a matrix of requirements that manufacturers must navigate. Product teams should align design specifications to the dominant combinations of technology, material, and end-user needs in their target geographies, while commercial teams should tailor channel strategies and service propositions to match the operational realities of hospitals, ambulatory centers, and home-based care providers.

Regional strategic imperatives that reconcile regulatory variation, clinical infrastructure, and manufacturing footprints to accelerate adoption of artificial lung technologies across global markets

Regional dynamics exert a powerful influence on regulatory expectations, reimbursement practices, and manufacturing logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical research networks and critical care infrastructure support advanced extracorporeal therapies, but market entry and scaling require navigation of diverse payer systems and hospital procurement protocols. Meanwhile, Europe, Middle East & Africa present a complex regulatory mosaic where harmonization efforts coexist with country-specific assessment criteria and procurement norms that shape deployment timelines and clinical evidence requirements.

Asia-Pacific markets demonstrate a spectrum of readiness, from high-volume, innovation-forward centers to regions prioritizing cost-effective and scalable solutions. Manufacturing capacity and supplier ecosystems in Asia-Pacific can offer competitive advantages for component sourcing, yet quality system alignment with international regulatory standards remains a critical gating factor. Across all regions, logistics, tariffs, and local clinical practice patterns inform decisions about regional production hubs, inventory positioning, and support infrastructure. Successful regional strategies integrate regulatory intelligence, localized clinical partnerships, and adaptive pricing models to align product value propositions with payer expectations and care delivery realities.

Organizations planning global rollouts should adopt a region-sensitive approach that sequences regulatory submissions, clinical engagements, and supply chain investments to reflect local priorities and operational constraints. This calibrated strategy reduces commercialization friction and accelerates meaningful clinical adoption across heterogeneous markets.

Key company patterns and competitive imperatives that prioritize membrane innovation, manufacturing rigor, clinical evidence generation, and channel orchestration for durable differentiation

Competitive dynamics in the artificial lung space are shaped by a mix of established medical device manufacturers, specialized component suppliers, and clinical innovators translating translational research into commercial prototypes. Key players invest in membrane science, pump efficiency, and integrated sensor systems to differentiate on performance, ease of use, and lifecycle costs. Strategic partnerships between device OEMs and materials specialists are increasingly common, enabling co-development of membrane structures and hemo-compatible coatings that reduce clot formation and inflammatory responses.

Beyond product innovation, companies that excel in commercialization are the ones that build robust clinical evidence generation programs and engage early with health technology assessment bodies. Manufacturing excellence and quality systems are equally critical; suppliers that can demonstrate scalable, reproducible production of membrane modules and precision pumps secure durable competitive advantages. Channel strategy also matters-organizations that combine direct clinical engagement with selective distributor relationships and digital platforms can extend reach while maintaining control over key customer interactions. Finally, leadership teams that prioritize post-market surveillance and iterative design improvements create a virtuous cycle of safety enhancements and clinician trust, which is especially important for devices that interface directly with blood and respiratory physiology.

High-impact recommendations for leaders to align modular engineering, supplier diversification, clinical evidence programs, and tailored commercial models to drive adoption and resilience

Industry leaders should pursue an integrated agenda that simultaneously addresses technological refinement, supply chain resilience, and clinical adoption pathways. Prioritizing modular device architectures will accelerate qualification of alternative suppliers and support iterative product updates without wholesale platform redesign. Investments in membrane and coating technologies should be coupled with rigorous hemocompatibility testing and human factors engineering to reduce adverse events and simplify clinician workflows. On the supply chain front, diversifying component sources and exploring regional manufacturing nodes can mitigate tariff exposure and logistical disruption while shortening lead times for critical assemblies.

Commercially, organizations should align go-to-market models to end-user needs by tailoring service bundles for hospitals, ambulatory centers, and home care settings, and by building training and remote-monitoring capabilities that lower barriers to adoption. Regulatory strategy must be proactive, embedding post-market data strategies and health economic modeling into submissions to demonstrate clinical utility and value to payers. Finally, leadership should institutionalize scenario-based planning to stress-test product roadmaps against policy shifts, supply interruptions, and payer behavior changes. These parallel actions will strengthen an organization's ability to convert engineering innovation into reliable, widely adopted clinical solutions.

A transparent, evidence-driven methodology integrating clinician interviews, materials and device analyses, supply chain mapping, and scenario testing to inform strategic decision-making

The research approach combines a multi-source evidence base, qualitative expert interviews, and structured analysis to create a comprehensive view of the artificial lung landscape. Primary inputs include discussions with clinicians, biomedical engineers, regulatory advisers, and procurement specialists to capture clinical workflows, device performance priorities, and real-world adoption barriers. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patents, and manufacturer technical specifications to triangulate technological trends and materials science advances. Comparative analysis of device architectures and supply chain footprints supports assessments of manufacturability and logistical risk.

Analytical methods include technology mapping to compare membrane types and pump platforms, value-chain decomposition to highlight cost and quality drivers, and scenario analysis to anticipate operational responses to policy shifts and tariff changes. Quality control measures include cross-validation of claims with multiple independent sources and critical appraisal of evidence quality for clinical outcomes. The methodology emphasizes transparency in assumptions and traceability of data sources while refraining from projecting numerical market estimates. This layered approach ensures the findings are grounded in empirical evidence and stakeholder perspectives, supporting actionable insights for developers, payers, and providers.

A conclusive synthesis that ties material science breakthroughs, device portability, regulatory alignment, and supply chain resilience into pragmatic pathways for clinical adoption and commercialization

In conclusion, advances in membrane materials, device miniaturization, and systems integration are converging to create an inflection point in artificial lung technologies, with implications for clinical practice, supply chain design, and commercialization strategies. The movement from exclusively in-hospital use toward ambulatory and potentially implantable applications requires a holistic approach that aligns engineering innovation with clinician workflows, regulatory compliance, and payer value assessment. Tariff dynamics and regional manufacturing considerations further underscore the need for resilient sourcing and near-market production options.

Stakeholders that adopt a segmented, regionally aware strategy-one that synchronizes product design, channel approach, and evidence generation-will be better positioned to navigate the complex path from prototype to clinical standard of care. Ultimately, the organizations most likely to succeed will be those that combine technical excellence in membrane and pump systems with disciplined commercialization practices, robust quality systems, and an adaptive supply chain capable of responding to policy and market shocks. This integrated posture will accelerate the translation of technological promise into tangible clinical benefits for patients with severe respiratory insufficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Lung Market, by Product Type

  • 8.1. Extracorporeal Membrane Oxygenation System
    • 8.1.1. Cannula
    • 8.1.2. Console
    • 8.1.3. Oxygenator
    • 8.1.4. Pump
  • 8.2. Implantable Artificial Lung

9. Artificial Lung Market, by Technology

  • 9.1. Ceramic Membrane
  • 9.2. Flat Sheet Membrane
  • 9.3. Hollow Fiber Membrane
    • 9.3.1. Polyethersulfone
    • 9.3.2. Polypropylene

10. Artificial Lung Market, by Material Type

  • 10.1. Polyethersulfone
  • 10.2. Polypropylene
  • 10.3. Silicone

11. Artificial Lung Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Care
  • 11.3. Hospitals

12. Artificial Lung Market, by Application

  • 12.1. Critical Care
  • 12.2. Emergency Transport
  • 12.3. Respiratory Support

13. Artificial Lung Market, by Distribution Channel

  • 13.1. Direct Sales
    • 13.1.1. Clinic Accounts
    • 13.1.2. Hospital Accounts
  • 13.2. Distributor Network
    • 13.2.1. Medical Device Distributors
    • 13.2.2. Pharmaceutical Distributors
  • 13.3. Online Platforms

14. Artificial Lung Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Lung Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Lung Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Artificial Lung Market

18. China Artificial Lung Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abiomed, Inc.
  • 19.6. ALung Technologies, Inc.
  • 19.7. B. Braun Melsungen AG
  • 19.8. Braile Biomedica
  • 19.9. Eurosets Srl
  • 19.10. Fresenius Medical Care AG & Co. KGaA
  • 19.11. Getinge AB
  • 19.12. Hemovent GmbH
  • 19.13. Inspira Technologies OXY B.H.N.
  • 19.14. LivaNova PLC
  • 19.15. MC3 Cardiopulmonary Support Inc.
  • 19.16. Medtronic PLC
  • 19.17. MicroPort Scientific Corporation
  • 19.18. Nipro Corporation
  • 19.19. Spectrum Medical (UK) Limited
  • 19.20. SynCardia Systems, LLC
  • 19.21. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL LUNG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL LUNG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2032 (USD MILLION)